ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma

1 hour ago 1

Healthcare

Comments

3D rendering of Natural Killer Cells attacking cancer

All five patients in a trial with recurrent glioblastoma given a combination of ImmunityBio's (NASDAQ:IBRX) natural killer (NK) cell therapy Anktiva and Novocure's (NASDAQ:NVCR) Optune Gio Tumor Treating Fields achieved 100% disease control.

The trial did not involve any chemotherapy

Recommended For You

More Trending News

Read Entire Article

ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma

Recommended For You

More Trending News

Related

Mitsubishi to pull out of three offshore wind projects in Ja...

TaskUs holder plans to vote against sale to Blackstone - rep...

Apple reveals iPhone 17 launch event's date and time

Furniture stocks rattled on Trump's threat of "substantial t...

Citi Trends outlines $40M EBITDA target by 2027 as store rem...

Meta to set up a California super PAC with focus on AI - Pol...

Despite snubbing U.S. tourism and boycotting American goods,...

Happy Belly Food Group reports Q2 results

Broadridge Financial reports insider transaction worth ~$1.5...

Gaotu projects Q3 2025 revenue growth of up to 30.6% while a...

Primior Holdings reports Q2 results

FLUENT reports Q2 results

Critical Metals, Ucore both rise on rare earths offtake agre...

Luca Mining reports Q2 results

P/F Bakkafrost reports Q2 results

Walmart adds next day delivery for third party orders; expan...

Trump’s threat to fire Fed Gov. Cook could lead to higher in...

Camden Property raised to Buy at Stifel as demand recovers

Perplexity, the $18 billion AI ‘answer machine’, wants to pl...

Maruti Suzuki's Gujarat plant a true example of 'Make in Ind...

Trending

Popular

عکس: قرار گرفتن نقشه بزرگ اوکراین در کاخ سفید

نرخ بهره بین بانکی به ۲۳.۹۹ درصد رسید+ جدول